Search Results for: Global Cancer Vaccine Market to
Articles
ISR Signs Agreement With Gerresheimer for Clinical-Scale Production of IcoOne Nasal Inhalers May 31, 2022
The drug development company ISR has recently signed an agreement with Gerresheimer for large-scale production of the IcoOne nasal inhaler, for its Phase 3 study of its dry powder….
SPECIAL FEATURE - PFS & Parenteral Drug Delivery: Self-Injection is Very Much the “New Normal” May 2, 2022
Contributor Cindy H. Dubin showcases how leading CDMOs and drug delivery developers are responding to current market trends to create ergonomic technologies that are patient friendly, easy to use, reduce needle anxiety, and feature improved packaging materials.
UK Government to Support Expansion of Croda’s Lipid Systems Manufacturing Facility April 4, 2022
Croda International Plc that uses smart science to create high performance ingredients and solutions that improve lives, recently announced that it has been awarded a £15.9 million grant by the UK Government to expand….
Recipharm Announces Acquisition of Vibalogics & Arranta Bio February 18, 2022
Recipharm is continuing to build its service offerings in new biologic modalities through the acquisition of Vibalogics and Arranta Bio….
SPECIAL FEATURE - Analytical Testing Trends in 2022 January 17, 2022
Contributor Cindy H. Dubin reports on the innovative technologies and techniques that several leading outsourcing providers currently offer for both small and large molecules.
Heat Biologics Announces Planned Acquisition of Elusys Therapeutics December 21, 2021
Heat Biologics, Inc. recently announced it has executed a definitive merger agreement to acquire Elusys Therapeutics, a commercial-stage biodefense company and the manufacturer of ANTHIM (obiltoxaximab) Injection,….
Fortress Biotech, Cyprium Therapeutics & Sentynl Therapeutics Announce the Initiation of Rolling Submission of an NDA for Treatment of Menkes Disease December 7, 2021
Cyprium Therapeutics, Inc., a Fortress Biotech, Inc. partner company, with support from its licensing partner Sentynl Therapeutics, Inc., a wholly owned subsidiary of Cadila Healthcare Limited, recently announced the initiation of a rolling submission of a New Drug Application….
DRUG DELIVERY - CAPRO(TM): A New Advance in Polymeric Drug Delivery October 4, 2021
Bob Wieden and Chun Wang, PhD, discuss how significant challenges, coupled with the complexity and diversity of new pharmaceuticals, have fueled the development of a novel polymeric drug delivery platform that overcomes a great many bioavailability and delivery obstacles.
Collaboration Between AbbVie, Biogen & Pfizer Creates World’s Largest Browsable Resource Linking Rare Protein-Coding Genetic Variants to Human Health & Disease July 8, 2021
Today, access to the world’s largest browsable resource linking rare protein-coding genetic variants to human health and disease was launched...OSE Immunotherapeutics Announces Manufacturing Agreement With Cenexi July 1, 2021
OSE Immunotherapeutics and Cenexi recently announced the signature of an agreement whereby Cenexi will manufacture clinical batches of CoVepiT, OSE Immunotherapeutics'...eTheRNA immunotherapies & Quantoom Biosciences Announce Strategic Collaboration for the Development of a Novel RNA Production June 30, 2021
eTheRNA immunotherapies NV and Quantoom Biosciences S.A. recently announced they are to collaborate on the development of a revolutionary RNA production system (RPS) for both research and GMP-grade material…..
BioNTech Announces First Patient Dosed in Phase 2 Clinical Trial of mRNA-Based BNT111 in Patients With Advanced Melanoma June 23, 2021
BioNTech SE recently announced the first patient has been treated in its BNT111 Phase 2 cancer vaccine trial (2020-002195-12; NCT04526899)....EXECUTIVE INTERVIEW - Micropore: Innovation in Drug Delivery May 3, 2021
Dai Hayward, CEO at Micropore, discusses his company’s expertise and underpinning technology in the development of safe, efficient, and scalable continuous manufacturing of drug delivery solutions.
Ridgeback Biotherapeutics & Merck Announce Preliminary Findings From Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir March 8, 2021
Merck and Ridgeback Biotherapeutics recently announced preliminary results from Ridgeback’s Phase 2a randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability, and efficacy to eliminate SARS-CoV-2 viral RNA….
SPECIAL FEATURE - Improving Bioavailability & Solubility: Each Molecule Is Unique March 1, 2021
Contributor Cindy H. Dubin speaks with several innovative companies to discuss novel approaches to improving bioavailability and solubility that have one commonality: they treat each molecule as an individual.
Halberd Collaborates With GreenBioAZ for the Development of Its Patent Pending Radio Frequency Technology February 24, 2021
Halberd Corporation has engaged GreenBioAZ, Inc. to conduct laboratory testing of Halberd’s patent-pending Radio Frequency (RF) extracorporeal treatment to eliminate...Halberd Collaborates With GreenBioAZ for the Development of Radio Frequency Technology to Eliminate Disease Pathogens February 17, 2021
Halberd Corporation has engaged GreenBioAZ, Inc. to conduct laboratory testing of Halberd’s patent pending Radio Frequency (RF) extracorporeal treatment to eliminate….
PLATFORM TECHNOLOGY - Morphomer(TM) & SupraAntigen(TM) Platforms: Targeting Misfolded Proteins in Neurodegenerative Disorders October 1, 2020
Andrea Pfeifer, PhD, details the efforts to develop the therapeutic and diagnostic tools necessary to enable precision medicine approaches targeting the right protein, at the right time, in the right patient.
Arctoris & Syntekabio Form Drug Discovery Research Partnership September 15, 2020
Arctoris has recently signed a Memorandum of Understanding with listed Korean company Syntekabio, Inc. to collaborate on drug discovery efforts....2020 Analytical Testing in Drug Development e-Book: A Critical Role in End-to-End Drug Development August 24, 2020
This second annual Drug Development & Delivery Analytical Testing eBook shines a light on analytical outsourcing providers that are optimizing testing solutions to ensure more robust results, speed time to market, and characterize methods earlier in development.
